Bracco Imaging Spa

Nationwide Study Confirms Safety of LUMASON® Ultrasound Enhancing Agent in Echocardiography

8 days ago

• A comprehensive real-world study analyzing over 11.4 million patients has validated the safety profile of ultrasound enhancing agents (UEAs) in echocardiographic procedures, with LUMASON® showing very low rates of serious complications. • The research, published in the Journal of the American Heart Association, demonstrated that LUMASON® use was associated with reduced odds of short-term mortality compared to unenhanced echocardiograms. • No significant differences in safety profiles were observed before, during, or after the COVID-19 pandemic, reinforcing the consistent reliability of LUMASON® across varying healthcare environments.

Blue Earth Therapeutics Secures $76.5M to Advance PSMA-Targeted Radioligand Therapies

7 months ago

• Blue Earth Therapeutics has secured $76.5M in Series A financing to advance its radiohybrid PSMA-targeted radioligand therapies. • The funding will support Phase II studies of Lutetium (177-Lu) rhPSMA-10.1 and Actinium (225-Ac) rhPSMA-10.1 for prostate cancer. • Blue Earth aims to compare its rhPSMA candidates with first-generation prostate cancer radioligand therapies to improve patient outcomes. • The investment reflects growing interest in the theranostics market, projected to reach $39 billion by 2032, driven by radiopharmaceuticals.